Relationship of detection rate of PET cancer screening examinees and risk factors: Analysis of background of examinees

Annals of Nuclear Medicine

Volumn 25, Issue 4, 2011, Pages 261-267

  Shibata, Koji ^a,b   Arai, Masami ^c   Matsuura, Masaaki ^d   Uno, Kimiichi ^a   Yoshida, Teruhiko ^e   Momose, Toshimitsu ^b   Ohtomo, Kuni ^b  

^a Nishidai Clinic Diagnostic Imaging Center   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d CANCER INSTITUTE   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Detection rate; Keywords PET cancer screening; Risk factors; Seeking bias

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DRINKING BEHAVIOR; FAMILY HISTORY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THYROID CANCER;

ADULT; AGED; BEHAVIOR; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 79959951682     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-010-0458-7     Document Type: Article

References (25)

1. Uno K, Jinnouchi S. Practice guidelines for PDG-PET cancer screening. Kaku Igaku. 2007; 44: 1-28.
2. 18Ffluorodeoxyglucose positron-emission tomography. Lancet. 1997; 350: 1819. (Pubitemid 28036519)
3. Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer. 2000; 83: 1607-11. (Pubitemid 32001701)
4. List of PET faculty (7 October 2009). Japanese Council of PET Imaging, 2009. http://www.jcpet.jp/1-3-4-1. Accessed 23 Nov 2009.
5. 18F-FDG-PET scans: The Nishidai clinic study. Eur J Cancer. 2007; 43: 1842-8. (Pubitemid 47238247)
6. Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med. 2007; 21: 481-98. (Pubitemid 350165651)
7. Kakizoe T. Gantaisakukihonnho To Nyugankenshin (fundamental law for anti-cancer measures and breast cancer screening). J Jpn Assoc Breast Cancer Screen. 2007; 16: 142-8 (in Japanese).
8. Weckesser M, Schober O. Is whole-body FDG-PET valuable for health screening? Against. Eur J Nucl Med Mol Imaging. 2005; 32: 342-3.
9. Silverman DHS. Comments and perspectives. Screening 18FFDG whole-body scanning: AWESOM-PET or FALSPOS-PET? J Nucl Med. 2005; 46: 717. (Pubitemid 43750743)
10. Ide M, Suzuki Y. Is whole-body FDG-PET valuable for health screening? For. Eur J Nucl Med Mol Imaging. 2005; 32: 339-41.
11. Katou K, Sakuta M. Smokefree policy of each 47 prefecture in 2007. Jpn J Tob Control. 2007; 2.
12. New Surgeon General's report expands list of smoking-related diseases. FDA Consum. 2004; 38: 9.
13. Eberl MM, Sunga AY, Farrell CD, Mahoney MC. Patients with a family history of cancer: identification and management. J Am Board Fam Pract. 2005; 18: 211-7. (Pubitemid 41657626)
14. Blot WJ. Alcohol and cancer. Cancer Res (Suppl). 1992; 52: 2119s-23s.
15. Stinson FS, DeBakey SF. Alcohol-related mortality in the United States, 1979-1988. Br J Addict. 1992; 87: 777-83.
16. Schoder H, Gonen M. Screening for cancer with PET and PET/ CT: potential and limitations. J Nucl Med. 2007; 48: 4S-18S. (Pubitemid 47604938)
17. 18F-2- deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report. Ann Nucl Med. 2008; 22: 379-85. (Pubitemid 351938513)
18. Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med. 2007; 21: 65-72. (Pubitemid 46280151)
19. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004; 231: 305-32. (Pubitemid 38552885)
20. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008; 3: 6-12.
21. Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med. 2005; 19: 167-77. (Pubitemid 40874507)
22. Jinnouchi M, Nakajo M, Tateno R, Tanabe H. Analysis of colon cancer detected in cancer screening with FDG-PET: comparing with feces occult blood test and CEA. Nihon Gan-Kenshinn Shindan Gakkaishi. 2007; 14: 150-5. (in Japanese).
23. Beinfeld MT, Wittenberg E, Gazelle GS. Cost-effectiveness of whole-body CT screening. Radiology. 2005; 234: 415-22. (Pubitemid 40139911)
24. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001; 176: 289-96. (Pubitemid 32105628)
25. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003; 362: 593-7. (Pubitemid 37013298)